![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ATHERSYS TO BEGIN TRIAL OF OBESITY DRUG
ATHERSYS TO BEGIN TRIAL OF OBESITY DRUG
August 14, 2006
Athersys has received approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase I study of ATHX-105, its lead obesity drug candidate.
In preclinical studies conducted by Athersys, ATHX-105 has demonstrated a significant reduction of food intake and weight loss in established obesity models and a good safety profile across multiple animal species.
Athersys plans to conduct the trial in healthy volunteers to assess the safety, tolerability and pharmacokinetics of ATHX-105. The study will be conducted in the United Kingdom at a site chosen for its substantial experience in obesity and conducting early-stage clinical studies.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct